专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010120578A1 MICRORNA AS A BIOMARKER OF PANCREATIC ISLET BETA-CELL ENGAGEMENT 审中-公开
标题翻译： MICRORNA作为PANCREATIC ISLET BETA-CELL参与的生物标记
公开(公告)号：WO2010120578A1
公开(公告)日：2010-10-21
申请号：PCT/US2010/029887
申请日：2010-04-05
申请人： MERCK SHARP & DOHME CORP. , ZHOU, Yun-Ping , HOWARD, Andrew, D. , SHANG, Jin
发明人： ZHOU, Yun-Ping , HOWARD, Andrew, D. , SHANG, Jin
IPC分类号： C12Q1/68
CPC分类号： C12Q1/686 , C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2525/207 , C12Q2521/107
摘要： MicroRNAs (miRNAs) are short non-coding RNAs that regulate gene expression and which play important roles in many cell types, including as described herein, the pancreatic β-cell. Glucagon like peptide-1 (GLP-1), a hormone released from intestinal L-cells following meal intake, exerts pleiotropic effects on β-cell function including raising intracellular cAMP levels and now represents an important therapy for type 2 diabetes. Expression of miR-132 and miR212 is upregulated by CREB protein in response increased cAMP levels in the cell; therefore, methods for detecting and evaluating β-cell engagement by GLP-1 receptor agonists by monitoring miR-132 and miR-212 expression in a subject is described. The methods herein are particularly useful in the context of longitudinal clinical trials, such as those designed for testing the durability of any single or combination therapy in type 2 diabetes populations. Because the expression of these miRNAs is not affected by glucose, fatty acid, insulin, or β-cell function, monitoring miR-132 and miR-212 expression can be used to monitor the efficacy of any agent that effects an increase cAMP in β-cells. Such agents include for example, GLP-1, glucagon, GPR-119, and GIP receptor agonists; dipeptidyl peptidase IV (DPP IV) inhibitors; and phosphodiesterase inhibitors.
摘要翻译：微小RNA（miRNA）是调节基因表达的短非编码RNA，其在许多细胞类型中起重要作用，包括本文所述的胰腺β细胞。胰高血糖素样肽-1（GLP-1）是膳食摄入后从肠道L细胞释放的激素，对β细胞功能具有多效性，包括提高细胞内cAMP水平，现在代表了2型糖尿病的重要疗法。 miR-132和miR212的表达由CREB蛋白上调，响应细胞中cAMP水平升高; 因此，描述了通过监测受试者中的miR-132和miR-212表达来检测和评估GLP-1受体激动剂的β细胞接合的方法。本文的方法在纵向临床试验的背景下特别有用，例如设计用于测试2型糖尿病人群中任何单一或联合疗法的耐久性的那些。由于这些miRNA的表达不受葡萄糖，脂肪酸，胰岛素或β细胞功能的影响，监测miR-132和miR-212的表达可用于监测影响ß- 细胞。这些药剂包括例如GLP-1，胰高血糖素，GPR-119和GIP受体激动剂; 二肽基肽酶IV（DPP IV）抑制剂; 和磷酸二酯酶抑制剂。

2. 发明公开

EP2419536A1 MICRORNA AS A BIOMARKER OF PANCREATIC ISLET BETA-CELL ENGAGEMENT 审中-公开
标题翻译：微RNA作为生物标记β细胞在胰腺癌群岛地区ENTRY
公开(公告)号：EP2419536A1
公开(公告)日：2012-02-22
申请号：EP10764903.0
申请日：2010-04-05
申请人： Merck Sharp & Dohme Corp.
发明人： ZHOU, Yun-Ping , HOWARD, Andrew, D. , SHANG, Jin
IPC分类号： C12Q1/68
CPC分类号： C12Q1/686 , C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2525/207 , C12Q2521/107
摘要： MicroRNAs (miRNAs) are short non-coding RNAs that regulate gene expression and which play important roles in many cell types, including as described herein, the pancreatic β-cell. Glucagon like peptide-1 (GLP-1), a hormone released from intestinal L-cells following meal intake, exerts pleiotropic effects on β-cell function including raising intracellular cAMP levels and now represents an important therapy for type 2 diabetes. Expression of miR-132 and miR212 is upregulated by CREB protein in response increased cAMP levels in the cell; therefore, methods for detecting and evaluating β-cell engagement by GLP-1 receptor agonists by monitoring miR-132 and miR-212 expression in a subject is described. The methods herein are particularly useful in the context of longitudinal clinical trials, such as those designed for testing the durability of any single or combination therapy in type 2 diabetes populations. Because the expression of these miRNAs is not affected by glucose, fatty acid, insulin, or β-cell function, monitoring miR-132 and miR-212 expression can be used to monitor the efficacy of any agent that effects an increase cAMP in β-cells. Such agents include for example, GLP-1, glucagon, GPR-119, and GIP receptor agonists; dipeptidyl peptidase IV (DPP IV) inhibitors; and phosphodiesterase inhibitors.

3. 发明申请

WO2006017171A2 METHODS OF DIAGNOSING & TREATING OBESITY, DIABETES AND INSULIN RESISTANCE 审中-公开
标题翻译：诊断和治疗肥胖，糖尿病和胰岛素抵抗的方法
公开(公告)号：WO2006017171A2
公开(公告)日：2006-02-16
申请号：PCT/US2005/024256
申请日：2005-07-07
申请人： METABOLEX, INC. , MOODIE, Shonna A. , ZHANG, Fang , RACK, Paul G. , SHANG, Jin , JOO, Daniel M. , WONG, Chi-Wai , GREGOIRE, Francine
发明人： MOODIE, Shonna A. , ZHANG, Fang , RACK, Paul G. , SHANG, Jin , JOO, Daniel M. , WONG, Chi-Wai , GREGOIRE, Francine
IPC分类号： A61K31/4439 , A61K31/426
CPC分类号： A61K31/426 , A61K31/4439 , G01N33/6893 , G01N2500/04 , G01N2800/042 , G01N2800/044
摘要： The present invention provides compositions and methods for diagnosing and treating obesity, diabetes and insulin resistance. In particular, the invention provides methods of identifying modulators of the polynucleotides or polypeptides of the invention and using those modulators to treat obesity and/or diabetes, as well as methods of diagnosing obesity and/or diabetes by measuring the levels of the polynucleotides or polypeptides of the invention in a patient.
摘要翻译：本发明提供了用于诊断和治疗肥胖，糖尿病和胰岛素抵抗的组合物和方法。特别地，本发明提供鉴定本发明的多核苷酸或多肽的调节剂并使用这些调节剂来治疗肥胖症和/或糖尿病的方法，以及通过测量多核苷酸或多肽的水平来诊断肥胖症和/或糖尿病的方法本发明在患者体内。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式